MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder

NCT04693351 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 589

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in participants with Obsessive Compulsive Disorder (OCD).

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Troriluzole

Capsules for oral administration.

DRUG

Placebo

Drug- matching capsules for oral administration.

Sponsors & Collaborators

  • Biohaven Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-29
Primary Completion
2025-04-29
Completion
2025-04-29
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04693351 on ClinicalTrials.gov